Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microparticles in Psoriasis Treated with Ustekinumab
NCT02693470Phase 4Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Aug 2014
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of ustekinumab in psoriasis (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Difference of CD41a and CD31 positive microparticles in patients with severe psoriasis before and after ustekinumab treatment at 4 months. Status: unknown.
02
Drugs
ustekinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02693470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02693470.